917341-47-0

Basic information

• Product Name: (2E)-N-(3,5-difluorophenyl)cinnamamide
• Synonyms: (2E)-N-(3,5-difluorophenyl)cinnamamide
• CAS NO: 917341-47-0
• Molecular Weight: 259.255
• Mol File: 917341-47-0.mol

Chemical Properties

• CAS DataBase Reference: (2E)-N-(3,5-difluorophenyl)cinnamamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-N-(3,5-difluorophenyl)cinnamamide(917341-47-0)
• EPA Substance Registry System: (2E)-N-(3,5-difluorophenyl)cinnamamide(917341-47-0)

Safety Data

• Hazardous Substances Data: 917341-47-0(Hazardous Substances Data)

Upstream product

• 140-10-3 (E)-3-phenylacrylic acid 
• 372-39-4 3,5-difluoroaniline 
• 102-92-1 Cinnamoyl chloride 
• 319-88-0 1,3,5-trichlorotrifluorobenzene 

Downstream Products

• 1188002-20-1 2-chloro-5,7-difluoroquinoline 

Relevant articles and documents

Interaction of polyfluorinated 2-chloroquinolines with ammonia

We have studied the interaction of polyfluorinated (in the benzene moiety) 2-chloroquinolines with liquid and aqueous ammonia as an approach to the synthesis of halogen-containing aminoquinolines. 5,7-Difluoro-, 5,6,8-trifluoro-, and 5,7,8-trifluoro-2-chloroquinolines mostly form products of substitution of the Cl atom, whereas 5,7-difluoro-2,6-dichloroquinoline, 5,6,7,8-tetrafluoro-, and 6,7-difluoro-2-chloroquinolines yield products of substitution of an F atom at various positions. The replacement of liquid ammonia with aqueous causes an increase in the proportion of the products of aminodechlorination relative to the products of aminodefluorination. For 2-chloro-6,8-difluoroquinoline this replacement leads to 2-amino-6,8-difluoroquinoline as the main product instead of the 8-amino-derivative. Activation energy values estimated by DFT calculations for the reactions in question agree with the reaction regioselectivity observed experimentally.

Synthesis, structure, and biological assay of cinnamic amides as potential EGFR kinase inhibitors

A series of derivatives of cinnamic amide (compounds 2a-2v) were synthesized and evaluated for antiproliferative activities against the human breast cancer cell line MCF-7- and EGFR-inhibitory activities. The structures of compounds 2b and 2i were determined by single-crystal X-ray diffraction analysis. Compounds 2f and 2j showed moderate EGFR inhibitory activity with IC50 values of 5.16 and 7.37 μM, respectively. Docking simulation of compound 2f was carried out to illustrate the binding mode of the molecule into the EGFR active site. Structure-activity relationship analysis found that the N-phenyl rings are required for enhancing the activities.

COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.